Aberrant survivin expression in endometrial hyperplasia: Another mechanism of progestin resistance

Xiaojun Chen, Zhenbo Zhang, Youji Feng, Oluwole Fadare, Jun Wang, Zhihong Ai, Hongyan Jin, Chao Gu, Wenxin - Zheng

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Up to 30% of failure rate in endometrial hyperplasia patients treated by progestin urges more detailed understanding of the mechanisms involved in progestin resistance. Survivin is a key regulator in the antiapoptotic network, and overexpression of survivin has been reported in endometrial hyperplasia and cancer. This study investigated the role of survivin in progestin resistance in endometrial hyperplasia. Pre- and post-treatment endometrial hyperplasia tissue samples from 23 women were examined for changes in survivin expression related to the administration of progestins. The impact of continuous or intermittent progestin treatment on survivin expression in Ishikawa cells was examined by the western blot. Survivin immunoreactivity was present in epithelial compartment of all pre-progestin-treated endometrial hyperplasia samples with mean nuclear indices 78 and cytoplasmic indices 114. In the 15 progestin responders, an average of 19.5-fold decrease of survivin expression was seen in epithelial nuclei (P 0.001) and 8-fold decrease in epithelial cytoplasm (P 0.001). In the eight non-responders, no significant changes in survivin expression were detected. With in vitro Ishikawa cells, survivin expression was effectively inhibited by either 72-h continuous treatment with 10 μM medroxyprogesterone acetate or 72 h after medroxyprogesterone acetate withdrawal. Our results indicated that dysregulation of survivin expression in hyperplastic endometrium may be part of the molecular mechanisms for progestin resistance. Intermittent, rather than continuous, progestin treatment may be more effective clinically for the treatment of endometrial hyperplasia.

Original languageEnglish (US)
Pages (from-to)699-708
Number of pages10
JournalModern Pathology
Volume22
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Endometrial Hyperplasia
Progestins
Medroxyprogesterone Acetate
Therapeutics
Endometrial Neoplasms
Endometrium
Cytoplasm
Western Blotting

Keywords

  • Endometrial cancer
  • Endometrial hyperplasia
  • Progestin
  • Progestin resistance
  • Survivin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Aberrant survivin expression in endometrial hyperplasia : Another mechanism of progestin resistance. / Chen, Xiaojun; Zhang, Zhenbo; Feng, Youji; Fadare, Oluwole; Wang, Jun; Ai, Zhihong; Jin, Hongyan; Gu, Chao; Zheng, Wenxin -.

In: Modern Pathology, Vol. 22, No. 5, 05.2009, p. 699-708.

Research output: Contribution to journalArticle

Chen, Xiaojun ; Zhang, Zhenbo ; Feng, Youji ; Fadare, Oluwole ; Wang, Jun ; Ai, Zhihong ; Jin, Hongyan ; Gu, Chao ; Zheng, Wenxin -. / Aberrant survivin expression in endometrial hyperplasia : Another mechanism of progestin resistance. In: Modern Pathology. 2009 ; Vol. 22, No. 5. pp. 699-708.
@article{c5318d71340142d284b5bdd65e8b71e2,
title = "Aberrant survivin expression in endometrial hyperplasia: Another mechanism of progestin resistance",
abstract = "Up to 30{\%} of failure rate in endometrial hyperplasia patients treated by progestin urges more detailed understanding of the mechanisms involved in progestin resistance. Survivin is a key regulator in the antiapoptotic network, and overexpression of survivin has been reported in endometrial hyperplasia and cancer. This study investigated the role of survivin in progestin resistance in endometrial hyperplasia. Pre- and post-treatment endometrial hyperplasia tissue samples from 23 women were examined for changes in survivin expression related to the administration of progestins. The impact of continuous or intermittent progestin treatment on survivin expression in Ishikawa cells was examined by the western blot. Survivin immunoreactivity was present in epithelial compartment of all pre-progestin-treated endometrial hyperplasia samples with mean nuclear indices 78 and cytoplasmic indices 114. In the 15 progestin responders, an average of 19.5-fold decrease of survivin expression was seen in epithelial nuclei (P 0.001) and 8-fold decrease in epithelial cytoplasm (P 0.001). In the eight non-responders, no significant changes in survivin expression were detected. With in vitro Ishikawa cells, survivin expression was effectively inhibited by either 72-h continuous treatment with 10 μM medroxyprogesterone acetate or 72 h after medroxyprogesterone acetate withdrawal. Our results indicated that dysregulation of survivin expression in hyperplastic endometrium may be part of the molecular mechanisms for progestin resistance. Intermittent, rather than continuous, progestin treatment may be more effective clinically for the treatment of endometrial hyperplasia.",
keywords = "Endometrial cancer, Endometrial hyperplasia, Progestin, Progestin resistance, Survivin",
author = "Xiaojun Chen and Zhenbo Zhang and Youji Feng and Oluwole Fadare and Jun Wang and Zhihong Ai and Hongyan Jin and Chao Gu and Zheng, {Wenxin -}",
year = "2009",
month = "5",
doi = "10.1038/modpathol.2009.25",
language = "English (US)",
volume = "22",
pages = "699--708",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Aberrant survivin expression in endometrial hyperplasia

T2 - Another mechanism of progestin resistance

AU - Chen, Xiaojun

AU - Zhang, Zhenbo

AU - Feng, Youji

AU - Fadare, Oluwole

AU - Wang, Jun

AU - Ai, Zhihong

AU - Jin, Hongyan

AU - Gu, Chao

AU - Zheng, Wenxin -

PY - 2009/5

Y1 - 2009/5

N2 - Up to 30% of failure rate in endometrial hyperplasia patients treated by progestin urges more detailed understanding of the mechanisms involved in progestin resistance. Survivin is a key regulator in the antiapoptotic network, and overexpression of survivin has been reported in endometrial hyperplasia and cancer. This study investigated the role of survivin in progestin resistance in endometrial hyperplasia. Pre- and post-treatment endometrial hyperplasia tissue samples from 23 women were examined for changes in survivin expression related to the administration of progestins. The impact of continuous or intermittent progestin treatment on survivin expression in Ishikawa cells was examined by the western blot. Survivin immunoreactivity was present in epithelial compartment of all pre-progestin-treated endometrial hyperplasia samples with mean nuclear indices 78 and cytoplasmic indices 114. In the 15 progestin responders, an average of 19.5-fold decrease of survivin expression was seen in epithelial nuclei (P 0.001) and 8-fold decrease in epithelial cytoplasm (P 0.001). In the eight non-responders, no significant changes in survivin expression were detected. With in vitro Ishikawa cells, survivin expression was effectively inhibited by either 72-h continuous treatment with 10 μM medroxyprogesterone acetate or 72 h after medroxyprogesterone acetate withdrawal. Our results indicated that dysregulation of survivin expression in hyperplastic endometrium may be part of the molecular mechanisms for progestin resistance. Intermittent, rather than continuous, progestin treatment may be more effective clinically for the treatment of endometrial hyperplasia.

AB - Up to 30% of failure rate in endometrial hyperplasia patients treated by progestin urges more detailed understanding of the mechanisms involved in progestin resistance. Survivin is a key regulator in the antiapoptotic network, and overexpression of survivin has been reported in endometrial hyperplasia and cancer. This study investigated the role of survivin in progestin resistance in endometrial hyperplasia. Pre- and post-treatment endometrial hyperplasia tissue samples from 23 women were examined for changes in survivin expression related to the administration of progestins. The impact of continuous or intermittent progestin treatment on survivin expression in Ishikawa cells was examined by the western blot. Survivin immunoreactivity was present in epithelial compartment of all pre-progestin-treated endometrial hyperplasia samples with mean nuclear indices 78 and cytoplasmic indices 114. In the 15 progestin responders, an average of 19.5-fold decrease of survivin expression was seen in epithelial nuclei (P 0.001) and 8-fold decrease in epithelial cytoplasm (P 0.001). In the eight non-responders, no significant changes in survivin expression were detected. With in vitro Ishikawa cells, survivin expression was effectively inhibited by either 72-h continuous treatment with 10 μM medroxyprogesterone acetate or 72 h after medroxyprogesterone acetate withdrawal. Our results indicated that dysregulation of survivin expression in hyperplastic endometrium may be part of the molecular mechanisms for progestin resistance. Intermittent, rather than continuous, progestin treatment may be more effective clinically for the treatment of endometrial hyperplasia.

KW - Endometrial cancer

KW - Endometrial hyperplasia

KW - Progestin

KW - Progestin resistance

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=67349131926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349131926&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.25

DO - 10.1038/modpathol.2009.25

M3 - Article

C2 - 19287462

AN - SCOPUS:67349131926

VL - 22

SP - 699

EP - 708

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -